dm+d

Unassigned

New Medicines

Primary biliary cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA)

Information

New molecular entity
Ipsen
Ipsen

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Dual peroxisome proliferator-activated alpha and delta receptor agonist (PPARα/δ agonist)
Autoimmune disease of biliary system; prevalence estimated as 12.9 per 100,000 population in the UK with up to 90% of cases occurring in women [2].
Primary biliary cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA)
Oral